Ivra is a drug owned by Apotex Inc. It is protected by 1 US drug patent filed in 2023 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 29, 2036. Details of Ivra's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10537520 | Stable liquid formulations of melphalan |
Jun, 2036
(11 years from now) | Active |
US patents provide insights into the exclusivity only within the United States, but Ivra is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Ivra's family patents as well as insights into ongoing legal events on those patents.
Ivra's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Ivra's generic launch date based on the expiry of its last outstanding patent is estimated to be Jun 29, 2036 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Ivra Generic API suppliers:
Melphalan Hydrochloride is the generic name for the brand Ivra. 16 different companies have already filed for the generic of Ivra, with Mylan Institutional having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Ivra's generic
Alternative Brands for Ivra
There are several other brand drugs using the same active ingredient (Melphalan Hydrochloride) as Ivra. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
Apart from brand drugs containing the same ingredient, some generics have also been filed for Melphalan Hydrochloride, Ivra's active ingredient. Check the complete list of approved generic manufacturers for Ivra
About Ivra
Ivra is a drug owned by Apotex Inc. Ivra uses Melphalan Hydrochloride as an active ingredient. Ivra was launched by Apotex in 2023.
Approval Date:
Ivra was approved by FDA for market use on 18 August, 2023.
Active Ingredient:
Ivra uses Melphalan Hydrochloride as the active ingredient. Check out other Drugs and Companies using Melphalan Hydrochloride ingredient
Dosage:
Ivra is available in solution form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 90MG BASE/ML (EQ 90MG BASE/ML) | SOLUTION | Prescription | INTRAVENOUS |